PDCD1 and gastric cancer: A programmed cell death protein 1 (PD-1) inhibitor, which suppresses the interaction between PD-1 and its ligands (programmed cell death protein‒ligand 1 [PD-L1] or PD-L2), has demonstrated encouraging antitumor activity in advanced GC.